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Abstract: The 2015 World Health Organization (WHO) Classification 
of Tumors of the Lung, Pleura, Thymus and Heart has just been pub-
lished with numerous important changes from the 2004 WHO clas-
sification. The most significant changes in this edition involve (1) use 
of immunohistochemistry throughout the classification, (2) a new 
emphasis on genetic studies, in particular, integration of molecular 
testing to help personalize treatment strategies for advanced lung can-
cer patients, (3) a new classification for small biopsies and cytology 
similar to that proposed in the 2011 Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory Society 
classification, (4) a completely different approach to lung adenocar-
cinoma as proposed by the 2011 Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory Society 
classification, (5) restricting the diagnosis of large cell carcinoma only 
to resected tumors that lack any clear morphologic or immunohisto-
chemical differentiation with reclassification of the remaining former 
large cell carcinoma subtypes into different categories, (6) reclassi-
fying squamous cell carcinomas into keratinizing, nonkeratinizing, 
and basaloid subtypes with the nonkeratinizing tumors requiring 
immunohistochemistry proof of squamous differentiation, (7) group-
ing of neuroendocrine tumors together in one category, (8) adding 
NUT carcinoma, (9) changing the term sclerosing hemangioma 
to sclerosing pneumocytoma, (10) changing the name hamartoma 
to “pulmonary hamartoma,” (11) creating a group of PEComatous 
tumors that include (a) lymphangioleiomyomatosis, (b) PEComa, 
benign (with clear cell tumor as a variant) and (c) PEComa, malig-
nant, (12) introducing the entity pulmonary myxoid sarcoma with an 
EWSR1–CREB1 translocation, (13) adding the entities myoepithe-
lioma and myoepithelial carcinomas, which can show EWSR1 gene 
rearrangements, (14) recognition of usefulness of WWTR1–CAMTA1 
fusions in diagnosis of epithelioid hemangioendotheliomas, (15) add-
ing Erdheim–Chester disease to the lymphoproliferative tumor, and 
(16) a group of tumors of ectopic origin to include germ cell tumors, 
intrapulmonary thymoma, melanoma and meningioma.
Key Words: WHO classification, Lung tumors, Lung cancer, Lung 
adenocarcinoma, Squamous cell carcinoma, Small cell carcinoma, 
Large cell carcinoma, Carcinoid.
(J Thorac Oncol. 2015;10: 1243–1260)
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has 
just been published (Table 1).1 This follows previous WHO 
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TABLE 1.  2015 WHO Classification of Lung Tumorsa,b,c
Histologic Type and Subtypes ICDO Code
Epithelial tumors
 Adenocarcinoma 8140/3
  Lepidic adenocarcinomae 8250/3d
  Acinar adenocarcinoma 8551/3d
  Papillary adenocarcinoma 8260/3
  Micropapillary adenocarcinomae 8265/3
  Solid adenocarcinoma 8230/3
  Invasive mucinous adenocarcinomae 8253/3d
   Mixed invasive mucinous and
   nonmucinous adenocarcinoma 8254/3d
  Colloid adenocarcinoma 8480/3
  Fetal adenocarcinoma 8333/3
  Enteric adenocarcinomae 8144/3
  Minimally invasive adenocarcinomae
   Nonmucinous 8256/3d
   Mucinous 8257/3d
  Preinvasive lesions
   Atypical adenomatous hyperplasia 8250/0d
   Adenocarcinoma in situe
    Nonmucinous 8250/2d
    Mucinous 8253/2d
 Squamous cell carcinoma 8070/3
  Keratinizing squamous cell carcinomae 8071/3
  Nonkeratinizing squamous cell carcinomae 8072/3
  Basaloid squamous cell carcinomae 8083/3
  Preinvasive lesion
   Squamous cell carcinoma in situ 8070/2
Neuroendocrine tumors
 Small cell carcinoma 8041/3
  Combined small cell carcinoma 8045/3
 Large cell neuroendocrine carcinoma 8013/3
  Combined large cell neuroendocrine carcinoma 8013/3
 Carcinoid tumors
  Typical carcinoid tumor 8240/3
  Atypical carcinoid tumor 8249/3
 Preinvasive lesion
  Diffuse idiopathic pulmonary neuroendocrine  
 cell hyperplasia
8040/0d
 Large cell carcinoma 8012/3
 Adenosquamous carcinoma 8560/3
 Sarcomatoid carcinomas
  Pleomorphic carcinoma 8022/3
  Spindle cell carcinoma 8032/3
  Giant cell carcinoma 8031/3
  Carcinosarcoma 8980/3
  Pulmonary blastoma 8972/3
 Other and Unclassified carcinomas
  Lymphoepithelioma-like carcinoma 8082/3
  NUT carcinomae 8023/3d
 Salivary gland-type tumors
  Mucoepidermoid carcinoma 8430/3
  Adenoid cystic carcinoma 8200/3
  Epithelial-myoepithelial carcinoma 8562/3
  Pleomorphic adenoma 8940/0
 Papillomas
  Squamous cell papilloma 8052/0
   Exophytic 8052/0
   Inverted 8053/0
  Glandular papilloma 8260/0
  Mixed squamous and glandular papilloma 8560/0
 Adenomas
  Sclerosing pneumocytomae 8832/0
  Alveolar adenoma 8251/0
  Papillary adenoma 8260/0
  Mucinous cystadenoma 8470/0
  Mucous gland adenoma 8480/0
Mesenchymal tumors
 Pulmonary hamartoma 8992/0d
 Chondroma 9220/0
 PEComatous tumorse
  Lymphangioleiomyomatosis 9174/1
  PEComa, benigne 8714/0
   Clear cell tumor 8005/0
  PEComa, malignante 8714/3
 Congenital peribronchial myofibroblastic tumor 8827/1
 Diffuse pulmonary lymphangiomatosis
 Inflammatory myofibroblastic tumor 8825/1
 Epithelioid hemangioendothelioma 9133/3
 Pleuropulmonary blastoma 8973/3
 Synovial sarcoma 9040/3
 Pulmonary artery intimal sarcoma 9137/3
 Pulmonary myxoid sarcoma with EWSR1–CREB1 translocatione 8842/3d
 Myoepithelial tumorse
  Myoepithelioma 8982/0
  Myoepithelial carcinoma 8982/3
Lymphohistiocytic tumors
 Extranodal marginal zone lymphomas of mucosa-associated  
 Lymphoid tissue (MALT lymphoma)
9699/3
 Diffuse large cell lymphoma 9680/3
 Lymphomatoid granulomatosis 9766/1
 Intravascular large B cell lymphomae 9712/3
 Pulmonary Langerhans cell histiocytosis 9751/1
 Erdheim–Chester disease 9750/1
Tumors of ectopic origin
 Germ cell tumors
  Teratoma, mature 9080/0
  Teratoma, immature 9080/1
 Intrapulmonary thymoma 8580/3
 Melanoma 8270/3
 Meningioma, NOS 9530/0
Metastatic tumors
aThe morphology codes are from the ICDO.2 Behavior is coded /0 for benign tumors, 
/1 for unspecified, borderline or uncertain behavior, /2 for carcinoma in situ and grade III 
intraepithelial neoplasia, and /3 for malignant tumors.
bThe classification is modified from the previous WHO classification3 taking into 
account changes in our understanding of these lesions.
cThis table is reproduced from the 2015 WHO Classification by Travis et al.1
dThese new codes were approved by the International Agency on Cancer Research/
WHO Committee for ICDO.
eNew terms changed or entities added since 2004 WHO Classification.3
LCNEC, large cell neuroendocrine carcinoma, WHO, World Health Organization; 
ICDO International Classification of Diseases for Oncology.
TABLE 1. (Continued)
Histologic Type and Subtypes ICDO Code
(Continued)
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Classifications of Lung Tumors in 1967 and 1981, of Lung 
and Pleural Tumors in 1999 and Tumors of the Lung, Pleura, 
Thymus and Heart in 2004.3–6 Due in part to remarkable 
advances in lung cancer genetics and therapy in the past decade, 
there are significant changes since the 2004 WHO classifica-
tion that will be summarized in this review.3 Compared with the 
2004 WHO Classification, there are multiple major changes for 
the common lung cancers most of which follow the 2011 lung 
adenocarcinoma classification sponsored by the International 
Association for the Study of Lung Cancer (IASLC), American 
Thoracic Society (ATS), and European Respiratory Society 
(ERS), which has essentially been adopted with only minor 
changes.7 The most significant changes in this edition compared 
with 2004 involve (1) use of immunohistochemistry through-
out the classification including for resected lung cancers, (2) 
a new emphasis on genetic studies, in particular integration of 
molecular testing to help personalize treatment strategies for 
advanced lung cancer patients, (3) a new classification for small 
biopsies and cytology as proposed by the 2011 IASLC/ATS/
ERS Classification with a different approach to classification 
of resected lung cancers, (4) a completely different approach 
to lung adenocarcinoma as proposed by the 2011 IASLC/ATS/
ERS Classification, (5) restricting the diagnosis of large cell car-
cinoma only to resected tumors that lack any clear morphologic 
or immunohistochemical differentiation with reclassification of 
the remaining former large cell carcinoma subtypes into differ-
ent categories, (6) reclassifying squamous cell carcinomas into 
keratinizing, nonkeratinizing and basaloid subtypes with the 
nonkeratinizing tumors requiring immunohistochemistry proof 
of squamous differentiation, (7) grouping of neuroendocrine 
tumors together in one category, (8) adding nuclear protein in 
testis (NUT) carcinoma to a category of other and unclassified 
tumors, (9) changing the term sclerosing hemangioma to scle-
rosing pneumocytoma and moving this tumor to the adenoma 
category, (10) changing the name hamartoma to “pulmonary 
hamartoma,” (11) creating a group of PEComatous tumors that 
include (a) lymphangioleiomyomatosis (LAM), (b) PEComa, 
benign (with clear cell tumor as a variant), and (c) PEComa, 
malignant, (12) introducing the entity pulmonary myxoid sar-
coma with an EWSR1–CREB1 translocation, (13) adding the 
entities myoepithelioma and myoepithelial carcinomas which 
can show EWSR1 gene rearrangements, (14) recognition of use-
fulness of WWTR1–CAMTA1 fusions in diagnosis of epithelioid 
hemangioendotheliomas (15) adding Erdheim–Chester dis-
ease to the lymphoproliferative tumors,1 and (16) a new group 
of tumors of ectopic origin was created to include germ cell 
tumors, intrapulmonary thymoma, melanoma and meningioma.
Much of the work of this classification was accom-
plished through the Pathology Committee of the IASLC, 
who supported annual meetings of the committee over the 
past decade and an international multidisciplinary meeting 
in December of 2014 in New York. This included meetings 
of the IASLC/ATS/ERS lung adenocarcinoma classification 
between 2008 and 2010 in which major changes were based 
on a systematic review of the literature and consensus major-
ity votes of the international multidisciplinary panel. For the 
WHO Book, lead authors were assigned to the major subchap-
ter topics, and they coordinated the development of consensus 
and the writing assignments among the assigned coauthors. 
In addition, all significant changes from the 2004 book were 
discussed and approved by majority voting during a consensus 
meeting sponsored by the WHO and International Agency on 
Cancer Research in Lyon, France in April of 2014.
MORE EXPANDED USE OF 
IMMUNOHISTOCHEMISTRY
In prior WHO classifications lung cancer diagnosis 
was based mainly on light microscopy using routine hema-
toxylin and eosin and sometimes mucin stained slides. 
Immunohistochemistry was introduced for the first time in the 
1999 WHO Classification and, even in the 2004 WHO classi-
fication, immunohistochemistry for lung cancer diagnosis was 
limited to large cell neuroendocrine carcinomas (LCNEC), sar-
comatoid carcinomas, and carcinomas in the differential diag-
nosis with malignant mesothelioma.3,6 However, throughout 
the 2015 WHO Classification, immunohistochemistry is now 
recommended, when possible, not only for small biopsies/cytol-
ogy, but also for resected specimens in certain settings such as 
solid adenocarcinoma, nonkeratinizing squamous cell carci-
noma, large cell carcinoma, neuroendocrine tumors, and sar-
comatoid carcinomas. With certain drugs approved for specific 
subgroups of non–small cell lung cancers (NSCLC) patients 
(i.e., bevacizumab, pemetrexed for nonsquamous histologies), 
the requirement for more exact histopathological subtyping is 
mandatory. Whenever immunohistochemistry is used in diag-
nosis, care must be taken to ensure high-quality staining and 
participation in a quality assurance program is recommended. 
Furthermore, care must be taken in the use of different antibody 
clones and in the interpretation of different degrees of staining.
NEW IMPORTANCE OF HISTOLOGY AND 
GENETICS FOR PERSONALIZED MEDICINE IN 
ADVANCED LUNG CANCER
One of the great advances in the past decade in lung 
cancer diagnosis and treatment is the concept of personalized 
medicine, where therapeutic decisions are based on the specific 
histologic and genetic characteristics of the patient’s tumor. This 
has given a new importance for pathologists to classify NSCLC 
further into specific pathologic subtypes (e.g., adenocarcinoma 
versus squamous cell carcinoma) as this determines eligibility 
for certain types of molecular testing and therapeutic strategies. 
Until the past decade, there have been no therapeutic implica-
tions to classify the NSCLC tumors further, so little attention 
was been given to the distinction of adenocarcinoma and squa-
mous cell carcinoma in small tissue samples. This situation 
changed dramatically with the discovery of several therapeutic 
options that are only approved for treatment of patients with 
specific histologic types. Discovery that epidermal growth fac-
tor (EGFR) mutations and anaplastic lymphoma kinase (ALK) 
rearrangements are effective targets for EGFR tyrosine kinase 
inhibitors or ALK inhibitors in patients with advanced lung ade-
nocarcinoma has not only revolutionized therapeutic strategies, 
but transformed clinical practice for pathologists.7 The new 
imperative for pathologists to distinguish between squamous 
cell carcinoma and adenocarcinoma was further emphasized 
by the observation that EGFR mutations and rearrangements 
of ALK and ROS1 are found primarily in adenocarcinoma, 
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that pemetrexed is effective in patients with advanced lung 
adenocarcinoma rather than squamous cell carcinoma, and that 
bevacizumab is contraindicated in patients with squamous cell 
carcinoma, whereas Nivolumab (a programmed death-ligand 
[PDL] antibody) was most recently approved by the U.S. Food 
and Drug Agency in patients with advanced lung squamous cell 
carcinoma.7,8 Because of the therapeutic implications, molecu-
lar testing for EGFR mutation and ALK rearrangement is today 
recommended by multiple leading clinical and pathology soci-
eties in tumors classified as adenocarcinoma and in cases where 
an adenocarcinoma component cannot be excluded.7,9,10
LUNG CANCER DIAGNOSIS IN SMALL BIOPSIES 
AND CYTOLOGY SPECIMENS
New criteria for the diagnosis of lung cancer based on 
small biopsies and cytology are proposed in the 2015 WHO 
classification. These guidelines are important because two 
thirds of lung cancer patients are presenting in advanced stages, 
and their diagnosis is usually established based on small biopsy 
and cytology specimens.7 Furthermore, it might be antici-
pated with the introduction of lung cancer screening that more 
patients, also in early stages of the disease, will be diagnosed 
based on small specimens. Furthermore, these specimens are 
needed not only for an accurate pathologic classification, but 
these small tissue samples also need to be managed carefully 
for molecular testing.7,9,10 This is the first WHO classification 
to provide standardized criteria and terminology for lung can-
cer diagnosis in small biopsies (bronchoscopic, needle, or core 
biopsies) and cytology (Tables 2 and 3).7 The previous 1967, 
1981, 1999, and 2004 WHO classifications addressed lung can-
cer classification based primarily on resection specimens.3–46 
Cytology was included for the first time in the 2004 WHO 
Classification; however, practical issues of diagnosing lung can-
cer in small biopsies were not addressed.3 Furthermore, because 
there was no clinical need to classify NSCLC further, the diag-
nosis of NSCLC without further specification was encouraged 
to avoid discrepancies with subsequent resected specimens. In 
small biopsies, the percentage of NSCLC cases diagnosed as 
not otherwise specified (NOS) has been as high as 30% to 50%, 
and recent data from the Surveillance Epidemiology and End 
Results registry suggests the frequency of this NOS diagnosis 
has been increasing over time.12–15 Until now, there have been no 
established standardized criteria or terminology for the diagno-
sis of lung cancer in small biopsies or cytology. However, over 
recent years, the situation has changed dramatically because 
of the major therapeutic implications of accurate histologic 
diagnosis and the need for molecular testing for eligibility to 
specific therapies. For this reason, it is recommended to reduce 
use of the term NSCLC NOS as much as possible and classify 
tumors according to their specific histologic subtype.7,11
TABLE 2.  Terminology and Criteria for Adenocarcinoma, Squamous Cell Carcinoma, and NSCC NOS in Small Biopsies and 
Cytology Compared with Terms in Resection Specimensa
New Small Biopsy/Cytology Terminology Morphology/Stains 2015 WHO Classification in Resection Specimens
Adenocarcinoma (describe identifiable 
patterns present)
Morphologic adenocarcinoma patterns 
clearly present
Adenocarcinoma predominant pattern: lepidic, acinar, papillary, 
solid, and micropapillary
Adenocarcinoma with lepidic pattern  
(if pure, add note: an invasive component 
cannot be excluded)
Minimally invasive adenocarcinoma, adenocarcinoma in situ, or 
an invasive adenocarcinoma with a lepidic component
Invasive mucinous adenocarcinoma 
(describe patterns present; use term 
mucinous adenocarcinoma with lepidic 
pattern if pure lepidic pattern)
Invasive mucinous adenocarcinoma
Adenocarcinoma with colloid features Colloid adenocarcinoma
Adenocarcinoma with fetal features Fetal adenocarcinoma
Adenocarcinoma with enteric featuresb Enteric adenocarcinoma
NSCC, favor adenocarcinomac Morphologic adenocarcinoma patterns not 
present but supported by special stains 
(i.e., TTF-1 positive)
Adenocarcinoma (solid pattern may be just one component  
of the tumor)
Squamous cell carcinoma Morphologic squamous cell patterns 
clearly present
Squamous cell carcinoma
NSCC, favor squamous cell carcinomac Morphologic squamous cell patterns not 
present but supported by stains (i.e., 
p40-positive)
Squamous cell carcinoma (nonkeratinizing pattern may be a 
component of the tumor)
NSCC NOSd No clear adenocarcinoma, squamous or 
neuroendocrine morphology or staining 
pattern
Large cell carcinoma
aModified from the articles by Travis et al.1,7,11
bMetastasis of colorectal cancer should be carefully excluded with judicious immunohistochemical stains and clinical evaluation.
cThese categories do not always correspond to solid adenocarcinoma or nonkeratinizing squamous cell carcinoma, respectively. Poorly differentiated components in adenocarcinoma 
or squamous cell carcinoma may be sampled.
dNSCC NOS pattern can be seen not only in large cell carcinomas but also when the solid poorly differentiated component of adenocarcinomas or squamous cell carcinomas is 
sampled but does not express immunohistochemical markers or mucin
NSCC, non–small cell carcinoma; NOS, not otherwise specified; TTF, thyroid transcription factor; WHO, World Health Organization.
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The specifics of the lung cancer classification in small 
biopsies and cytology are explained in more detail else-
where.7,11 Briefly, tumors that have clear morphologic patterns 
of adenocarcinoma (acinar, papillary, lepidic, micropapillary) 
or squamous cell carcinoma (unequivocal keratinization and 
well formed classical bridges) can be diagnosed as adeno-
carcinoma or squamous cell carcinoma, respectively, without 
immunohistochemistry, unless a pneumocyte marker such as 
thyroid transcription factor (TTF)-1 is desired to address pri-
mary versus metastatic adenocarcinoma (Table 2). However, 
in the setting of poorly differentiated tumors that do not show 
clear differentiation by routine microscopy, a limited immuno-
histochemical workup is recommended to allow for an accurate 
diagnosis and also to preserve as much tissue for molecular 
testing as possible. Most tumors can be classified using a 
single adenocarcinoma marker (e.g., TTF-1 or mucin) and a 
single squamous marker (e.g., p40 or p63). Non‒small cell 
carcinomas (NSCC, without the L for lung) that show no clear 
adenocarcinoma or squamous cell carcinoma morphology or 
immunohistochemical markers are regarded as NSCC not oth-
erwise specified (NOS). In this setting, it is recommended that 
pathologists use the term NSCC rather than NSCLC, because 
the lack of pneumocyte marker expression in small biopsies 
or cytology leaves open the possibility of a metastatic carci-
noma and the determination of a lung primary must be estab-
lished clinically after excluding other primary sites. If tumor 
with this morphology stains with pneumocyte markers (i.e., 
TTF-1), it is classified as NSCC, favor adenocarcinoma, and 
if it stains only with squamous markers (i.e., p40), it is clas-
sified as NSCC, favor squamous cell carcinoma (Table 2). In 
this way, application of immunohistochemistry increases the 
refinement of diagnosis so that a diagnosis of NSCC NOS can 
be avoided in up to 90% of cases.13,14 In cases that meet crite-
ria for NSCC NOS, consideration should be given for using 
a limited immunohistochemical panel to confirming a carci-
noma (e.g., cytokeratin versus S100 or CD45) or a metastasis 
(estrogen receptor, prostate specific antigen, paired box 8). 
Terminology to be used in small biopsies for other major cat-
egories of lung cancer is summarized in Table 3.7,11
It is recognized that not all laboratories worldwide will 
have access to immunohistochemistry, or even a mucin stain, 
and in this setting, the diagnosis of NSCC NOS may remain 
frequent. However, the current classification still needs to 
encompass scientific advances where they can impact patient 
care. Accepted markers for identification of differentiation 
toward adenocarcinoma are TTF-113,14,16 and Napsin-A,17 both 
of which are approximately 80% sensitive, although TTF-1 is 
easier to assess as a nuclear stain. In relation to squamous dif-
ferentiation, P40 is reported as the most specific and sensitive 
squamous marker.18–20 Other previously recommended anti-
bodies include cytokeratin 5/6 and P63.13,14 A reasonable rec-
ommendation is that, when immunohistochemistry is deemed 
necessary, at least one antibody each for squamous and glan-
dular differentiation, but no more than two antibodies, should 
be used for an initial workup in each case (e.g., TTF-1 and P40 
or P63).11,21 Thus a simple panel of TTF-1 and p40 may be able 
to classify most NSCC NOS cases. If these stains are negative, 
further evaluation to confirm a diagnosis of carcinoma and to 
exclude a metastasis is appropriate. If TTF-1 reactivity is pres-
ent in one population of tumor cells and another population 
is positive for squamous markers, this may raise the possibil-
ity of adenosquamous carcinoma, although this diagnosis can 
only be made based on a resection specimen.
Need to Apply New WHO Criteria in Future 
Clinical Trials and Genetic Studies
There is a great need for these new terminology and 
diagnostic criteria for small biopsies and cytology to be 
TABLE 3.  Diagnostic Terminology for Small Biopsy/Cytology Compared with the 2015 WHO Terms in Resection Specimens 
with Small Cell Carcinoma, LCNEC, Adenosquamous Carcinoma, and Sarcomatoid Carcinomaa
Small Biopsy/Cytology Terminology/Criteria 2015 WHO Classification in Resections
Small cell carcinoma Small cell carcinoma
NSCC with NE morphology and positive NE markers, possible LCNEC LCNEC
NSCC with NE morphology
If negative NE markers comment: This is a NSCC where LCNEC is 
suspected, but stains failed to demonstrate NE differentiation.
Large cell carcinoma with NE morphology (LCNEM)
Morphologic squamous cell and adenocarcinoma patterns present:
NSCC, NOS
Comment that adenocarcinoma and squamous components are present 
and this could represent adenosquamous carcinoma.
Adenosquamous carcinoma (if both components ≥10%)
Morphologic squamous cell or adenocarcinoma patterns not present 
but immunostains favor separate glandular and adenocarcinoma 
components: NSCC, NOS
Specify the results of the immunohistochemical stains and the 
interpretation and comment this could represent adenosquamous 
carcinoma.
Adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma or large 
cell carcinoma with unclear immunohistochemical features
NSCC with spindle cell and/or giant cell carcinoma (mention if 
adenocarcinoma or squamous carcinoma are present)
Pleomorphic, spindle cell, and/or giant cell carcinoma
aModified from the articles by Travis et al.1,7,11
LCNEC, large cell neuroendocrine carcinoma; NOS, not otherwise specified; NSCC, non–small cell carcinoma; NE, neuroendocrine; WHO, World Health Organization.
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applied in clinical trials of patients with advanced lung can-
cers.22 Unfortunately, most of the existing clinical trial data 
regarding histology are based on studies where some cases 
would be reclassified if this new approach were applied. For 
example, some of the data regarding pemetrexed efficacy in 
cancers other than squamous cell carcinoma and regarding the 
toxicity of bevacizumab in squamous cell carcinomas need to 
be reevaluated with the new criteria.
In addition, future large-scale genetic studies such as The 
Cancer Genome Atlas need to incorporate the new criteria for 
both small biopsies and resection specimens, which now require 
immunohistochemistry to precisely classify poorly differenti-
ated tumors such as solid adenocarcinoma or nonkeratinizing 
squamous cell carcinoma.1 This was not possible with the recent 
lung squamous cell carcinoma and adenocarcinoma The Cancer 
Genome Atlas projects,23,24 but, fortunately, this was done with 
the Clinical Lung Cancer Genome Project, which allowed 
for precise classification of the tumors that resulted in critical 
genetic data to guide some of the key revisions in the current 
WHO Classification, particularly for large cell carcinoma.25
Histologic Grading of Lung Cancer
There is no established histologic grading system for most 
lung cancers. Some tumors such as neuroendocrine tumors are 
inherently graded as they are classified with low-grade typical 
carcinoid, intermediate-grade atypical carcinoid, and high-grade 
LCNEC and small cell carcinoma. Other tumors such as large 
cell carcinoma and pleomorphic carcinoma are always high 
grade. In resection specimens, proposals have been made for 
grading lung adenocarcinoma using architectural versus nuclear 
approaches or a combination of both.26–30 At the moment, grad-
ing according to the single most predominant pattern appears to 
be a simple and sufficient approach. Most studies show lepidic 
adenocarcinomas are low grade; acinar and papillary tumors 
are intermediate grade; solid and micropapillary tumors are 
high grade.31,32 However, it would be useful to stratify further 
the intermediate-grade acinar and papillary adenocarcinomas, 
and this may be a good role for nuclear grading and mitotic 
counts.27–29,33,34 However, more investigation is needed to address 
which approach is clinically relevant. For resected squamous cell 
carcinomas, there is very little data available, but nuclear diam-
eter has been shown to be an independent predictor of worse 
outcome.35 In one cytologic study, nuclear grading provided 
prognostic distinctions in aspiration biopsies.36 Tumor budding 
has been recently reported to be an independent prognostic 
factor in both lung adenocarcinoma and squamous cell carci-
noma.35,37–39 In conclusion, there is a great need for additional 
studies of histological grading in lung cancer.
LUNG CANCER CLASSIFICATION IN RESECTION 
SPECIMENS
The remainder of this discussion regarding lung cancer 
primarily addresses diagnosis and classification in resection 
specimens. In some of these tumors such as adenocarcinoma 
in situ (AIS) and minimally invasive adenocarcinoma (MIA), 
large cell carcinoma, adenosquamous carcinoma, and pleo-
morphic carcinoma, the diagnosis cannot be made without 
complete evaluation of the entire tumor histologically.
ADENOCARCINOMA
Major Changes in Adenocarcinoma Classification
In 2011, a new IASLC/ATS/ERS classification of lung 
adenocarcinoma proposed significant changes to the 2004 
WHO classification for resected tumors including (1) discon-
tinuing the terms bronchioloalveolar carcinoma (BAC) and 
mixed subtype adenocarcinoma; (2) the addition of AIS as a 
preinvasive lesion to join atypical adenomatous hyperplasia; 
(3) addition of MIA, (4) classification of invasive adenocarci-
nomas according to the predominant subtype after comprehen-
sive histologic subtyping by semiquantitatively estimating the 
percentage of the various subtypes present in 5% increments; 
(5) use of the term “lepidic” for a noninvasive component 
(previously classified as BAC) present as part of an invasive 
adenocarcinoma; (6) introducing the term “invasive mucinous 
adenocarcinoma” for adenocarcinomas formerly classified as 
mucinous BAC, excluding tumors that meet criteria for AIS 
or MIA; (7) discontinuing the subtypes of clear cell and sig-
net ring adenocarcinoma and recognizing these as a feature 
when any amount is present, however small; (8) discontinuing 
the term mucinous cystadenocarcinoma and including these 
under the category of colloid adenocarcinoma.3,7,11,40
Subsequent to the 2011 IASLC/ATS/ERS lung adeno-
carcinoma classification and with the development of the 2015 
WHO classification, it was decided to classify tumors formerly 
called large cell carcinomas that have pneumocyte marker 
expression (i.e., TTF-1 and/or Napsin A), as solid adenocarci-
noma even if mucin is absent.1 Solid adenocarcinoma must be 
distinguished from squamous cell carcinomas and large cell 
carcinomas, both of which may show rare cells with intracel-
lular mucin. Solid adenocarcinoma should show at least two 
high-power fields with five or more cells showing intracyto-
plasmic mucin. The expression of TTF-1 and/or Napsin-A is 
sufficient not only for diagnosing solid adenocarcinoma, but 
for separating it from squamous cell carcinoma.41,42
Criteria for diagnosis of AIS and MIA are summarized 
in Tables 4 and 5. With regard to the term lepidic, resected 
TABLE 4.  Adenocarcinoma In Situa
Diagnostic criteria
• A small tumor ≤3 cma
• A solitary adenocarcinoma
• Pure lepidic growth
• No stromal, vascular or pleural invasion
• No pattern of invasive adenocarcinoma (such as acinar, papillary,  
 micropapillary, solid, colloid, enteric, fetal or invasive mucinous  
 adenocarcinoma).
• No spread through air spaces
• Cell type mostly nonmucinous (type II pneumocytes or Clara cells),  
 rarely may be mucinous (tall columnar cells with basal nuclei and  
 abundant cytoplasmic mucin, sometimes resembling goblet cells).
• Nuclear atypia is absent or inconspicuous
• Septal widening with sclerosis/elastosis is common, particularly in  
 nonmucinous adenocarcinoma in situ
aModified from the articles by Travis et al.1,7,11
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primary lung adenocarcinomas that are lepidic predominant 
invasive adenocarcinoma should be called “adenocarcinoma, 
lepidic subtype” or “lepidic adenocarcinoma” with mention of 
the percentage of the lepidic component and listing of each 
of the other patterns present with their estimated percentage. 
Measurement of invasive size can be challenging in tumors 
with a lepidic component. If there is a single focus of invasion 
in a small tumor, it can be measured microscopically with a 
ruler on top of the slide on the microscope stage. If there are 
multiple foci of invasion or if the tumor does not fit onto a 
single slide, making ruler measurements difficult, recent data 
suggest that another way to estimate the invasive size is to sum 
the percentage of the invasive components and multiply this by 
the overall tumor diameter (i.e., a 2.0-cm total tumor size with 
20% invasive components and 80% lepidic component would 
have an estimated invasive size of 2.0 × 0.2 = 0.4 cm).43 In the 
differential with MIA, if the result is greater than 5 mm, a diag-
nosis of lepidic adenocarcinoma should be rendered. If there 
is doubt about tumor size after review of pathologic slides, 
correlation with a high-resolution computed tomography (CT) 
may be helpful to appreciate the amount of solid versus ground 
glass components in a lung nodule as these generally corre-
spond to invasive versus lepidic components histologically.
The diagnosis of AIS or MIA can only be made in a 
resected tumor that has been submitted entirely for histologic 
evaluation, so complete histologic review can be performed to 
look for invasive foci. Therefore, when a small biopsy shows 
only a nonmucinous lepidic pattern, the diagnosis should be 
“adenocarcinoma with lepidic pattern” (Fig. 1A) adding a com-
ment that this could be from a lesion that represents AIS, MIA, 
or invasive adenocarcinoma with a lepidic component (i.e., 
adenocarcinoma, lepidic subtype, or an invasive adenocarci-
noma with a non-predominant lepidic component). Rarely, 
metastatic tumors may show a lepidic pattern, but they do not 
typically express TTF-1 in addition to the morphology of type 
II pneumocytes and/or club (Clara) cells. Correlation with 
CT findings can be informative to the likely final diagnosis 
(Fig. 1B). For example, if a biopsy shows a lepidic pattern and 
the CT shows a pure ground glass nodule, this would favor AIS 
or possibly MIA and less likely lepidic predominant adeno-
carcinoma (Fig. 1B), whereas if a mostly ground glass nodule 
also had a solid component measuring over 5 mm in size were 
present, this would favor lepidic predominant adenocarcinoma 
(Fig. 1C).44–47 However, the final diagnosis of AIS or MIA 
requires a resection specimen, and these cannot be diagnosed 
in small biopsy specimens. It is reasonable to sample possible 
AIS or MIA lesions to save frozen tissue for research, but cor-
relation with the CT findings should be made to be sure there 
are no suspicious solid areas for invasion. If suspicious areas 
are seen on CT and they are not represented in the histologic 
slides, the frozen sample may need to be processed for histo-
logic examination to allow for a definitive diagnosis.
As most of the literature on MIA and AIS deals with 
tumors less than or equal to 2 to 3 cm, there is insufficient 
evidence that 100% disease-free survival can occur with such 
TABLE 5.  Minimally Invasive Adenocarcinomaa
Diagnostic criteria
• A small tumor ≤3 cm
• A solitary adenocarcinoma
• Predominantly lepidic growth
• ≤0.5 cm invasive component in greatest dimension in any one focus
• Invasive component to be measured includes
 °  Any histologic subtype other than a lepidic pattern (such as acinar, 
papillary, micropapillary, solid, colloid, fetal or invasive mucinous 
adenocarcinoma)
 ° Tumor cells infiltrating myofibroblastic stroma
• Minimally invasive adenocarcinoma diagnosis is excluded if the tumor
 ° Invades lymphatics. blood vessels, air spaces or pleura,
 ° Contains tumor necrosis,
 ° Spreads through air spaces
• The cell type mostly nonmucinous (type II pneumocytes or Clara cells), 
but rarely may be mucinous (tall columnar cells with basal nuclei and 
abundant cytoplasmic mucin, sometimes resembling goblet cells).
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tumors greater than 3 cm.7,40 Therefore, if a tumor larger than 
3 cm has been completely sampled histologically and shows 
either no invasion or less than or equal to 0.5 cm of invasion, 
the tumor should be classified as “lepidic adenocarcinoma, 
suspect AIS or MIA,” respectively.
In the 2015 WHO classification, the term “predomi-
nant” is not listed in the name for the major adenocarcinoma 
subtypes as it was in the 2011 IASLC/ATS/ERS lung adeno-
carcinoma classification. However, these tumors still should 
be classified according to the predominant subtype after eval-
uation of the tumor using comprehensive histologic subtyp-
ing to make a semiquantitative estimate of all of the different 
histologic patterns present in 5% increments. Classification of 
tumors according to the predominant subtype should not be 
interpreted to imply these are specific entities. Because lung 
adenocarcinomas frequently are composed of complex het-
erogeneous mixtures of patterns with a continuum from one 
pattern to the next (i.e., lepidic to papillary or acinar), com-
prehensive histologic typing provides a useful tool to estimate 
not only the predominant pattern but also minor components. 
It is very useful to document these percentages in pathology 
reports as it helps to document cases where there are small 
amounts of the micropapillary pattern, which have been shown 
to be associated with poor prognosis even in small amounts as 
it helps to compare multiple adenocarcinomas to document 
whether the percentages of patterns is similar or different.48 
Even though it is theoretically possible to have equal percent-
ages of two prominent components, in practice, a single pre-
dominant component should be chosen. Recording of these 
percentages in a pathologic diagnosis in such a case makes it 
clear to the reader of a report when a tumor has relatively even 
mixtures of several patterns versus a clear single predominant 
pattern. One point of frequent questioning is when an area of 
adenocarcinoma shows an acinar or lepidic pattern, and there 
are tumor cells within air spaces in a micropapillary pattern; 
this should be classified as micropapillary and not acinar or 
lepidic (Fig. 2). Several studies have shown that the cribriform 
pattern is associated with worse prognosis.49–51 Recognition 
of this pattern may be a way to recognize a higher grade of 
tumors with acinar growth.
A reproducibility study of classical and difficult 
selected images of the major lung adenocarcinoma subtypes 
circulated among a panel of 26 expert lung cancer patholo-
gists documented κ- values of 0.77 ± 0.07 and 0.38 ± 0.14, 
respectively.52 A study of reproducibility for predominant pat-
tern showed moderate to good κ-values of 0.44 to 0.72 for 
pulmonary pathologists. For untrained pathologists, κ-values 
were expectedly lower ranging from 0.38 to 0.47, but these 
improved after a training session to 0.51 to 0.66 and reevalua-
tion by the same reviewers led to very high κ-values between 
0.79 and 0.87.53
Spread Through Air Spaces
Since the 2011 IASLC/ATS/ERS lung adenocarcinoma 
classification was published, an additional pattern of invasion 
is now more clearly recognized consisting of spread through 
air spaces (STAS). STAS consists of micropapillary clusters, 
solid nests, or single cells beyond the edge of the tumor into air 
spaces in the surrounding lung parenchyma (Fig. 3). It prob-
ably contributes to the significantly increased recurrence rate 
for patients with small stage 1 adenocarcinomas who undergo 
limited resections54 and the worse prognosis observed by oth-
ers.55–57 As this represents a manifestation of tumor spread, this 
is not included in the percentage measurement of subtype pat-
terns in comprehensive histologic typing or in measurement of 
invasive size. STAS is now incorporated into the definition of 
invasion that is used to separate lepidic adenocarcinomas from 
MIA and AIS. STAS is a pattern of invasion to be reported 
similar to visceral pleural and vascular invasion.
Comparing Multiple Lung Adenocarcinomas
Comprehensive histologic subtyping can be useful in 
comparing multiple lung adenocarcinomas in a single patient 
to distinguish multiple primary tumors from intrapulmonary 
metastases. This has a great impact on staging for patients 
with multiple lung adenocarcinomas. Recording the percent-
ages of the various histologic subtypes in 5% increments, not 
just the most predominant type, allows these data to be used to 
compare multiple adenocarcinomas, particularly if the slides 
of a previous tumor are not available at the time of review 
of the additional lung tumors. In addition to comprehensive 
histologic subtyping, other histologic features of the tumors 
such as cytologic (clear cell or signet ring features) or stromal 
(desmoplasia or inflammation) characteristics may be helpful 
to compare multiple tumors.48 It is likely that poorly differen-
tiated components such as solid and micropapillary may be 
enriched in some metastatic foci, so one does not necessar-
ily expect an identical percentage distribution of patterns in 
intrapulmonary metastases, and in such cases, other stromal 
or cytologic characteristics may play a more important role. 
Nevertheless this is a powerful tool for morphologic compari-
son of multiple tumors. Several genetic studies have addressed 
this problem,48,58–63 but the role of molecular studies includ-
ing what platform to utilize and how to interpret the results 
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approach is needed to address this problem incorporating 
clinical, radiologic, molecular, and pathologic information.
Prognostic and Predictive Implications of 
Adenocarcinoma Comprehensive Subtyping
Despite the challenges in distinguishing some patterns 
from each other, since the principle of comprehensive histo-
logic subtyping was introduced in the 2011 IASLC/ATS/ERS 
classification, there are a growing number of studies of resected 
lung adenocarcinomas that have demonstrated its utility in 
identifying significant prognostic subsets and molecular cor-
relations according to the predominant patterns.31,32,43,64–69 The 
prognosis for lepidic predominant adenocarcinoma in stage I 
patients is excellent31,32,43,69,70; most of those tumors that recur 
have some high risk factor such as a close margin in limited 
resection and presence of a micropapillary component or inva-
sion of blood vessels and/or pleura.43 The solid and micropapil-
lary subtypes are associated with poor prognosis.64,66–68,70,71 The 
presence of the micropapillary subtype is a poor prognostic 
factor for overall survival72 and for recurrence in patients with 
limited resections.73 Solid predominant subtype has also been 
shown to be an independent predictor of early, extrathoracic, 
multisite recurrence, and poor postrecurrence survival.74
New data suggest that micropapillary or solid predomi-
nant subtyping predicts improved responsiveness to adjuvant 
chemotherapy compared with acinar or papillary predominant 
tumors in surgically resected lung adenocarcinoma patients 
when analyzed by disease-free survival and specific disease-
free survival.75
SqUAMOUS CELL CARCINOMA
The terminology and criteria for squamous cell carci-
noma diagnosis in small biopsies are discussed above, and 
the comments below refer to these issues in resection speci-
mens. In the 2004 WHO classification, the major subtypes 
included papillary, clear cell, small cell, and basaloid carci-
noma. However, this was not very meaningful as the papillary, 
clear cell, and small cell subtypes are very uncommon.35 In 
retrospect, the term small cell variant of squamous cell car-
cinoma was probably not a good choice because if it were 
used in clinical practice, it could be confused with small cell 
carcinoma, so this term is now discontinued. As with lung 
adenocarcinoma, clear cell change is now regarded as a cyto-
logic feature that can occur in keratinizing or nonkeratinizing 
squamous cell carcinoma, so this is no longer recognized as a 
formal subtype, although it can be referred to in a diagnosis 
as “with clear cell features” with the amount mentioned even 
if in a small percentage. In addition, with the new importance 
of separating adenocarcinoma and squamous cell carcinoma, 
it was learned through molecular and immunohistochemical 
studies that some adenocarcinomas have a very squamous-like 
morphology.41,42 So in the absence of unequivocal keratiniza-
tion, immunohistochemistry with positive squamous markers 
such as p40 or p63 is required to diagnose surgically resected 
nonkeratinizing squamous cell carcinoma. Furthermore, with 
the recognition that the former basaloid carcinomas actually 
express squamous markers, these tumors were moved from the 
category of large cell carcinoma to become a subtype of squa-
mous cell carcinoma. Genetic data also support that basaloid 
squamous cell carcinomas show a specific mRNA expression 
profile, factors controlling cell cycle, transcription, chromatin, 
and splicing with prevalent expression in germ line and stem 
cells and underexpress typical genes seen in other squamous 
cell carcinomas.76 For these reasons, the subtyping of squa-
mous cell carcinoma was modified to consist of keratinizing, 
nonkeratinizing, and basaloid subtypes, similar to the Head 
and Neck WHO Classification of nasopharyngeal carcinomas 
(Table 1).77 Tumors are classified as keratinizing subtype if 
any amount of keratinization is present and basaloid squa-
mous cell carcinoma if this component is greater than 50% 
of the tumor, regardless of the presence of any keratinization. 
In tumors with 50% or less of a basaloid component, this can 
be acknowledged in the diagnosis “with basaloid features.”1 
There does not seem to be prognostic significance to keratin-
izing versus nonkeratinizing squamous carcinomas.35 Some 
studies suggest a poorer prognosis for basaloid squamous cell 
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There is currently no clear clinical implication to the 
subtyping of squamous cell lung cancer. However, there is an 
increasing amount of clinical data on new therapies for this 
tumor (e.g., immunotherapy and new targeted therapies).82
LARGE CELL CARCINOMA
The entity large cell carcinoma can only be diagnosed in 
a surgical resected tumor, so this term should not be applied to 
small biopsies or cytology (see above). In the 2004 WHO clas-
sification, large cell carcinoma included several variants such 
as LCNEC, basaloid carcinoma, lymphoepithelioma-like carci-
noma, clear cell carcinoma, and large cell carcinoma with rhab-
doid phenotype.3 In addition, in the 2004 WHO Classification, 
there was no role for immunohistochemistry using adenocarci-
noma or squamous markers in assessing these tumors. However, 
in the 2015 WHO Classification, carcinomas showing a solid 
pattern are now reclassified as solid adenocarcinoma or non-
keratinizing squamous cell carcinoma, if they show positive 
staining for markers such as TTF-1 or p40, respectively.1 This 
decision was based on genetic and immunohistochemical stud-
ies indicating that tumors previously classified as large cell 
carcinomas were a heterogeneous group of tumors with adeno-
carcinoma, squamous cell differentiation, or a null immuno-
phenotype and genotype.21,83,84 Poorly differentiated carcinomas 
are regarded to have a null immunophenotype if they lack clear 
pneumocyte (i.e., TTF-1), squamous (p40), or neuroendocrine 
(chromogranin, synaptophysin, CD56) marker staining patterns. 
Tumors with adenocarcinoma or null immunophenotype typi-
cally showed an adenocarcinoma genetic profile, and those with 
a squamous immunophenotype showed a squamous genetic 
profile.21,83–85 Furthermore, epidemiologic evidence from the 
National Cancer Institute (NCI) Surveillance Epidemiology and 
End Results registry indicated that the diagnosis of large cell 
carcinoma started to decline about the time that TTF-1 was intro-
duced into clinical diagnosis, so this probably reflects that prac-
ticing pathologists started to reclassify large cell carcinomas.86
The other large cell carcinoma subtypes from the 2004 
WHO classification are reclassified as follows. LCNEC is now 
grouped with the other neuroendocrine tumors. Basaloid car-
cinoma is moved to a subtype of squamous cell carcinoma. 
Lymphoepithelioma-like carcinoma is moved to a group of 
“other and unclassified carcinomas.” Clear cell carcinoma and 
rhabdoid phenotype are now regarded as a cytologic features 
rather than a specific histologic subtype, as these can occur 
in a variety of histologic types including adenocarcinoma or 
squamous cell carcinoma (Table 1).
NEUROENDOCRINE TUMORS
In the 1981, prior WHO classifications the carcinoid 
tumors, small cell lung carcinoma (SCLC) and LCNEC were 
grouped separately. However, in the current classification they 
are grouped together.1 The tumors are listed in the order of 
their frequency with SCLC first as it is the most common. 
Although some have suggested there should be a uniform neu-
roendocrine tumor classification system throughout the body 
including the lung, similar to the one used in the gastrointes-
tinal tract and pancreas, a leading organization, the European 
Neuroendocrine Tumor Society, has endorsed the WHO clas-
sification for pulmonary neuroendocrine tumors.87
Despite the grouping of these tumors together, it is clear 
that the carcinoids have major clinical, epidemiologic, histologic, 
and genetic differences compared with the high-grade SCLC 
and LCNEC. Carcinoid patients are significantly younger, have 
a better prognosis, and lack the strong association with smok-
ing that applies for SCLC and LCNEC. Also compared with 
carcinoid tumors, SCLC and LCNEC have much higher mitotic 
rates, more necrosis and can show combinations with other lung 
cancer types including adenocarcinoma or  squamous cell carci-
noma.87 Carcinoid tumors also have very few genetic abnormali-
ties compared with SCLC and LCNEC.85,88
Although, in many cases, SCLC and carcinoid tumors 
can be diagnosed on good quality tumor material with a high-
quality hematoxylin and eosin–stained section and in well pre-
served cytologic samples, immunohistochemistry can be very 
helpful in diagnosing pulmonary neuroendocrine tumors. The 
role of Ki-67 is mainly to separate the high-grade SCLC and 
LCNEC from the carcinoid tumors, especially in small biop-
sies with crushed and/or necrotic tumor cells.89,90 Data are 
conflicting regarding its use in separating typical from atypical 
carcinoid tumors, so it is not recommended in this setting.87,89,91
Mitosis counting methods were not specified in the 2004 
WHO Classification, but more detail is provided in the 2015 book. 
Careful counting of mitoses is essential as it is the most impor-
tant histologic criteria for separating typical from atypical carci-
noid and the carcinoids from the high-grade SCLC and LCNEC. 
Mitoses should be counted in the areas of highest activity and 
per 2 mm2 rather than 10 high-power fields. Because of the dif-
ferences in microscope models, adjustments need to be made in 
the number of high-power fields reviewed to assess a 2 mm2 area 
of tumor.92 In tumors that are near the cutoffs of 2 or 20 mitoses 
per 2 mm2, at least three sets of 2 mm2 should be counted and the 
mean used for determining the mitotic rate, rather than the single 
highest rate. For typical and atypical carcinoid tumors, mitotic 
rate and necrosis status should be included in pathology reports.
Because of recognition of the potential overlap in the 
morphology of LCNEC and basaloid squamous cell carci-
noma, it can be helpful to confirm negative squamous markers 
(i.e., p40) in TTF-1–negative tumors that otherwise meet cri-
teria for LCNEC. In 10-20% of NSCC, neuroendocrine differ-
entiation can be demonstrated. This is not formally recognized 
as class of tumors in the 2015 WHO Classification, as there is 
no proven clinical  significance to this finding.1,3,7
SARCOMATOID CARCINOMA
Sarcomatoid carcinoma is a general term that includes 
pleomorphic carcinoma, carcinosarcoma, and pulmonary blas-
toma. For this reason, it is best to use the specific term for these 
entities whenever possible rather than the general term. This also 
may avoid any confusion with a true sarcoma. These tumors are 
rare accounting for less than 1% of all lung cancers.93 There are 
no major changes in the terminology or diagnostic criteria for 
these tumors since the 2004 Classification. One new aspect is 
the recommendation for molecular testing according to known 
genetic abnormalities associated with histologic components 
(i.e., tumors with an adenocarcinoma component should be 
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tested for EGFR mutation and ALK rearrangement). The diag-
noses of pleomorphic, spindle cell, or giant cell carcinoma 
cannot be made on small biopsies or cytology, and recommen-
dations for diagnostic terminology in these types of specimens 
are discussed above. It is very difficult to diagnose carcinosar-
coma or pulmonary blastoma in small biopsies and cytology, 
but if material is obtained that fulfills diagnostic criteria, it is 
possible. Prognosis for all these tumors is poor.
Pleomorphic carcinoma is a poorly differentiated NSCC 
namely a squamous cell carcinoma, adenocarcinoma, or undif-
ferentiated NSCC that contains at least 10% spindle and/or 
giant cells or a carcinoma consisting only of spindle and giant 
cells. The prevalence of KRAS (in up to 38% of cases)94,95 and 
EGFR mutations (in up to 25% of cases)96–98 partially reflects 
the tumor components (i.e., adenocarcinoma), patient ethnic-
ity, and smoking habits.99
Spindle cell carcinoma consists of an almost pure popu-
lation of epithelial spindle cells, with no differentiated carci-
nomatous elements.
Giant cell carcinoma consists almost entirely of tumor 
giant cells (including multinucleated cells), with no differenti-
ated carcinomatous elements. Definite diagnosis may only be 
made on a resected tumor. The specific histological compo-
nents should be mentioned in the diagnosis.
Carcinosarcoma is a malignant tumor that consists of 
a mixture of NSCLC (typically squamous cell carcinoma or 
adenocarcinoma) and sarcoma-containing heterologous ele-
ments, such as rhabdomyosarcoma, chondrosarcoma, and 
osteosarcoma. Carcinosarcomas are clonal tumors100–102 devel-
oping through sarcomatoid change in a carcinoma.100,102 TP53 
mutations are often present in carcinosarcoma,101,103 whereas 
KRAS mutations occur less frequently,101,103 and EGFR muta-
tions are very uncommon.103,104
Pulmonary blastoma is a biphasic tumor that consists of 
fetal adenocarcinoma (typically low grade) and primitive mes-
enchymal stroma. Foci of specific mesenchymal differentia-
tion (osteosarcoma, chondrosarcoma, or rhabdomyosarcoma) 
may also be present but are not required for the diagnosis. 
Pulmonary blastoma and well-differentiated fetal adenocarci-
noma (a putative precursor lesion) are frequently associated 
with missense mutations in exon 3 of CTNNB1, responsible 
for activation of the Wnt pathway through aberrant nuclear/
cytoplasmic localization of β-catenin protein.103,105–107 TP53 
mutation and both p53 and MDM2 protein accumulation are 
occasionally detected in pulmonary blastoma.101,103,108
NUT CARCINOMA
Carcinomas associated with chromosomal rearrangement 
in the NUT gene are called NUT carcinomas. These are poorly 
differentiated carcinomas genetically defined by the presence of 
NUT gene rearrangement.109,110 This consists of a chromosomal 
translocation between the NUT gene (NUTM1) on chromosome 
15q14 and other genes: BRD4 on chromosome 19p13.1 (70%), 
BRD3 on chromosome 9q34.2 (6%), or an unknown partner 
gene (24%).111 Fewer than 100 cases of NUT carcinoma have 
been reported. Although it was originally thought to be a dis-
ease of children and younger adults, NUT carcinoma can affect 
people of any age, affecting males and females equally.109,110
This tumor was recognized in the thymus in the 2004 
WHO classification as a carcinoma with t(15;19) transloca-
tion, and it is also referred to as NUT midline carcinoma. 
Pathologically, it consists of sheets and nests of small-sized to 
intermediate-sized undifferentiated cells with a monomorphic 
appearance (Fig. 4A).110 Nuclei have irregular contours and 
granular to coarse chromatin. Foci of abrupt keratinization 
are often present. Immunohistochemistry is positive in more 
than 50% of tumor cells with a speckled nuclear positivity 
(Fig. 4B).112 NUT carcinoma is a very aggressive tumor with a 
median survival of 7 months.113
TUMORS OTHER THAN LUNG CANCER WITH 
SIGNIFICANT CHANGES FROM THE 2004 WHO 
CLASSIFICATION
Sclerosing Pneumocytoma
In this classification, sclerosing hemangioma is moved 
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classified in both the 1999 and 2004 WHO Classifications3,6 to 
the group of “Adenomas” in the current classification. It has 
been recognized for many years that sclerosing hemangioma 
is not a vascular tumor. Multiple papers have documented 
that this tumor is actually derived from primitive respiratory 
epithelial cells that express TTF-1 in the solid as well as sur-
face tumor cells.114,115 This tumor characteristic has become 
widely recognized and accepted making it an appropriate time 
to reclassify this tumor as an adenoma. Sclerosing pneumo-
cytoma is a tumor of pneumocytic origin with a dual popu-
lation of surface cells resembling type II pneumocytes and 
round cells, with slightly different histogenetic profiles. Most 
tumors have at least three of four primary growth patterns: 
solid, papillary, sclerosing, and hemorrhagic. The key fea-
ture of sclerosing pneumocytoma is the presence of two cell 
types: cuboidal surface cells and stromal round cells, both of 
which are considered to be neoplastic.116 The surface cells are 
cuboidal and morphologically similar to type II pneumocytes. 
These tumors can be very challenging to diagnose in frozen 
section, small biopsies, and cytology where they can easily be 
mistaken for adenocarcinoma or carcinoid tumors. Despite the 
very rare frequency of metastases, these tumors typically have 
a benign clinical course.114
Pulmonary Hamartoma
Pulmonary hamartomas are neoplasms composed of 
varying amounts of at least two mesenchymal elements (such 
as cartilage, fat, connective tissue, and smooth muscle), com-
bined with entrapped respiratory epithelium. Because ham-
artomas in other parts of the body are generally not regarded 
to be neoplasms, there was a debate if hamartomas in the 
lung should have an International Classification of Diseases 
for Oncology code in this classification. However, because 
multiple genetic studies have established that these are true 
neoplasms, they have been assigned a new International 
Classification of Diseases for Oncology code and the diag-
nostic term is “pulmonary hamartoma,” rather than just ham-
artoma. Pulmonary hamartomas have a high frequency of the 
translocation t(3;12)(q27-28;q14-15), resulting in gene fusion 
of the high mobility group protein gene HMGA2 and the 
LPP gene. The HMGA2–LPP fusion gene usually consists of 
exons 1–3 of HMGA2 and exons 9–11 of LPP and seems to be 
expressed in all tumors with this translocation.117–119
Pulmonary hamartomas are composed predominantly 
of chondroid or chondromyxoid tissue intermixed with vari-
able proportions of other mesenchymal components, includ-
ing fat, myxoid fibrous connective tissue, smooth muscle, 
and bone. Clefts of normal respiratory epithelial cells rep-
resent entrapment by the expanding mesenchymal growth. 
Endobronchial pulmonary hamartomas may have a promi-
nent adipose tissue component. Immunohistochemical 
stains show reactivity for mesenchymal markers and sex 
steroid receptors, but immunohistochemistry is not usually 
necessary for diagnosis.120
PEComatous Tumors
PEComatous tumors are thought to arise from peri-
vascular epithelioid cells. In the lung, they can take several 
forms: (1) a diffuse multicystic proliferation termed LAM; (2) 
more rarely, a benign localized mass termed a clear cell tumor 
or PEComa; and (3) exceptionally, a diffuse proliferation 
with overlapping features between LAM and clear cell tumor. 
These lesions are part of the spectrum of PEComatous tumors 
that arise at several sites throughout the body, originating from 
the perivascular epithelioid cells, although no counterpart 
in normal tissue has yet been identified. In the 1999 WHO6  
Classification, LAM was classified under tumor-like lesions, 
and in 2004,3 it was moved to mesenchymal tumors. In both 
1999 and 2004 WHO Classifications, clear cell tumors were 
grouped under “Miscellaneous tumors.” However, in the 2015 
WHO Classification, these lesions are grouped together under 
the title “PEComatous tumors” with three groups of tumors: 
(1) LAM, (2) PEComa, benign including clear cell tumor, and 
(3) PEComa, malignant.1 Historically LAM was considered 
an interstitial lung disease but it is now considered to be a 
low-grade destructive metastasizing neoplasm, as the lesional 
cells usually have growth-promoting biallelic mutations in the 
tuberous sclerosis gene TSC2. Lymphangioleiomyomatosis 
cells also show evidence of clonal origin, as well as invasive 
and metastatic potential further supporting the theory of a 
neoplastic underpinning.121–124 There is a very rare association 
between clear cell tumors and tuberous sclerosis.125 Isolated 
cases with more diffuse features that overlap with LAM have 
also been described,126 called diffuse PEComatosis.127
Lymphangioleiomyomatosis consists of a prolifera-
tion of plump spindle-shaped myoid cells with typically 
pale eosinophilic cytoplasm. These are usually found in the 
walls of the cystic air spaces, where their growth may be 
overt and nodular, although some cases may be very subtly 
infiltrative, to the extent that multiple levels are required to 
identify the lesional cells. Lesional cells may infiltrate blood 
vessels and lymphatics, causing secondary pulmonary hem-
orrhage. Lymphangioleiomyomatosis can be associated with 
micronodular type II pneumocyte hyperplasia, particularly in 
individuals with tuberous sclerosis.128 Clear cell tumors consist 
of rounded or oval cells with distinct cell borders and abun-
dant clear or eosinophilic cytoplasm. There is mild variation 
in nuclear size, and nucleoli may be prominent, but mitoses 
are usually absent.129,130 The presence of necrosis is extremely 
rare and should lead to consideration of malignancy,126,129,131 
as should significant mitotic activity and an infiltrative growth 
pattern. Thin-walled sinusoidal vessels are characteristic. 
Because of the glycogen-rich cytoplasm, there is usually 
strong periodic acid–Schiff positivity that is removed with dia-
stase digestion.132 Cases with diffuse PEComatosis show fea-
tures overlapping between LAM and clear cell tumor.127 Both 
LAM and clear cell tumor stain most consistently for HMB45, 
melan A, and microphthalmia transcription factor. Clear cell 
tumors may also stain for S100. Lymphangioleiomyomatosis 
stains for smooth muscle actin and is S100-negative; some 
cases also stain for the estrogen and progesterone receptors. 
The TSC mutations that occur in LAM result in abnormal sig-
naling through the mammalian target of rapamycin (mTOR) 
pathway.133
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Epithelioid Hemangioendothelioma
Epithelioid hemangioendothelioma is a low-grade to 
intermediate-grade malignant vascular tumor composed of 
solid nests and short cords of epithelioid endothelial cells in a 
myxohyaline stroma.134,135 The new information regarding this 
tumor is recognition of a translocation involving the WWTR1 
and CAMTA1 genes and prognostic factors. The details of the 
histologic features are described previously.3,134,135 They may 
be low or intermediate grade with the latter distinguished by 
the presence of necrosis, increased mitotic activity (mean 
2/2 mm2), and greater nuclear atypia.134 The vascular markers 
CD31, CD34, and FLI1 are more sensitive than factor vIII, 
and most epithelioid hemangioendothelioma expresses these 
markers. Focal cytokeratin expression is present in 25% to 
30% of cases.134 A recurrent t(1;3)(p36.3;q25) chromosomal 
translocation is characteristic of epithelioid hemangioendo-
thelioma.134,136 The translocation involves two genes, WWTR1 
(3q25), which encodes a transcriptional coactivator that is 
highly expressed in endothelial cells, and CAMTA1 (1p36), 
a DNA-binding transcriptional regulatory protein that is nor-
mally expressed during brain development.137–139 A subset of 
epithelioid hemangioendothelioma occurring in young adults 
shows recently described YAP1–TFE3 fusions.140 Epithelioid 
hemangioendothelioma is a low-grade to intermediate-grade 
malignant tumor with metastatic potential and a 5-year sur-
vival rate of 60%. Prognosis is worse for intermediate grade 
compared with low-grade tumors and can be as low as 20%.134 
Negative prognostic indicators include extensive intrapulmo-
nary and pleural spread, weight loss, anemia, and hemorrhagic 
pleural effusions.141
Pulmonary Myxoid Sarcoma with 
an EWSR1–CREB1 Translocation
Primary pulmonary myxoid sarcoma is a malignant 
tumor that typically arises in the airways. It predominantly 
consists of lobules of delicate, lacelike strands, and cords of 
mildly atypical round and spindle cells within a prominent 
myxoid stroma. Primary pulmonary myxoid sarcoma was 
first described in 1999.142 It is seen most often in young adult 
females, but fewer than 15 cases have been published.143,144 The 
tumor is characterized by distinct histological features and an 
EWSR1–CREB1 fusion (Fig. 5). Although EWSR1–CREB1 is 
also found in other tumors (such as angiomatoid fibrous his-
tiocytoma144 and clear cell sarcomas),145 primary pulmonary 
myxoid sarcomas are morphologically different from these 
entities. At low power, pulmonary myxoid sarcomas have a 
lobulated architecture, with an endobronchial location. A 
fibrous pseudocapsule may be present. Tumors are typically 
composed of spindle, stellate, and polygonal cells, with a pre-
dominant reticular network of delicate lacelike strands and 
cords within a prominent myxoid stroma that may be lightly 
basophilic, although more solid areas may be found. A minor-
ity have a predominantly solid architecture with a more pat-
ternless distribution of cells within the myxoid stroma, which 
may be focally fibrous (Fig. 5A). In one case, cells showed 
focal multinucleation. Cellular atypia is generally mild to 
moderate in extent, although rare cases have shown focal 
marked atypia and multinucleation. Mitotic rates of up to 32 
mitoses per 2 mm2 with atypical forms are described, although 
the majority shows less than 5 mitoses per 2 mm2. Necrosis is 
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have a patchy background chronic inflammatory cell infiltrate 
of mainly lymphocytes and plasma cells. vascular invasion is 
rare.143 All tumors express vimentin, and 60% show weak and 
focal staining for epithelial membrane antigen. Other com-
mon markers are negative, in particular cytokeratins, S100, 
smooth muscle actin, desmin, CD34, and neuroendocrine 
markers. The myxoid stroma is positive for Alcian blue, with 
staining sensitive to treatment with hyaluronidase.142
EWSR1 rearrangements are detectable by fluorescent 
in situ hybridization, with real-time reverse transcriptase 
polymerase chain reaction analysis showing EWSR1–CREB1 
fusion transcripts that have been confirmed with direct 
sequencing (Fig. 5, B and C). In assessable cases, the break 
point in EWSR1 involved exon 7, whereas for the CREB1 gene, 
exon 7 was involved in six cases and exon 8 in one. Cases 
have been assessed for fusion transcripts of NR4A3EWSR1 
and NR4A3TAF15, but neither were detected.143
Myoepithelial Tumors
Myoepithelial tumors of the lung are rare, but they are 
gaining increasing recognition with the discovery of EWSR1 
gene rearrangements as a marker. These tumors show pre-
dominant or exclusive myoepithelial differentiation, and 
malignant myoepithelial tumors are classified as myoepi-
thelial carcinomas. Myoepithelial tumors differ from mixed 
tumors, in that mixed tumors also show ductal differentiation. 
Histologically, the tumors show a spectrum of trabecular or 
reticular patterns, with abundant myxoid stroma (Fig. 6).146–151 
The tumor cells are epithelioid or spindled, and the nuclei are 
uniform, with eosinophilic or clear cell cytoplasm (Fig. 6). 
Cells with a plasmacytoid appearance and cytoplasmic hya-
line inclusions can be present.146,147 Myoepithelial carcino-
mas also show malignant features, such as a high mitotic 
rate, necrosis, or nuclear atypia.148,151 Immunohistochemistry 
shows that most tumors stain positively for keratin, S100, 
calponin, and glial fibrillary acidic protein. Smooth muscle 
actin and p63 (or p40) may also be positive. Staining for 
desmin and CD34 is negative.134,146,147 EWSR1 gene rear-
rangement can be found in pulmonary myoepithelial tumors 
EWSR1–ZNF444, and FUS gene rearrangements were found 
in two malignant tumors that showed clear cell and spindle 
cell morphology.152
Erdheim–Chester disease
Erdheim–Chester disease is newly added to the classifi-
cation of lymphoproliferative disorders as it has become better 
characterized clinically, pathologically, and genetically. It is a 
rare xanthogranulomatous histiocytosis characterized by infil-
tration of the skeleton and viscera by lipid-laden histiocytes. In 
the lung, this leads to interstitial fibrosis with a perilymphatic 
distribution. Erdheim–Chester disease involves the lungs in 
20% to 30% of patients,153,154 and there is a slight male predomi-
nance. Peak incidence occurs within the fifth to seventh decade, 
with a range of 4 to 87 years and a mean age at diagnosis of 
53 years.153–156 Pulmonary symptoms are typically cough and 
dyspnea, although pulmonary involvement may also be asymp-
tomatic.153 Pleural effusions occur in about 20% of patients.155 
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associated with soft tissue swelling), fever, weight loss, and 
weakness. Other manifestations include exophthalmos, diabe-
tes insipidus, kidney failure, and cardiac or neurological symp-
toms. The serum lipid profile is relatively normal. The lung is 
involved in more than half of all cases with thoracic involve-
ment, with septal and subpleural thickening, poorly defined 
centrilobular nodular, and ground-glass opacities, and lung 
cysts being reported.155,157 Mediastinal infiltration, pleural thick-
ening, and effusions are also commonly seen.157 Architecturally, 
histiocytic infiltration and fibrosis predominate along the distri-
bution of the pulmonary lymphatics (visceral pleura, broncho-
vascular bundles, and interlobular septa; Fig. 7A). Histiocytes 
are typically foamy, with Touton giant cells often seen (Fig. 7B). 
This is associated with variably dense fibrosis, lymphocytes, 
plasma cells, and eosinophils. Immunohistochemistry confirms 
the monocyte/macrophage lineage of the lipid-laden foamy his-
tiocytes and giant cells by their expression of Factor XIIIa, lyso-
zyme, MAC387, CD68 (KP1), CD4, alpha-1 antichymotrypsin, 
alpha-1 antitrypsin, and S100 protein (variable).158 They are 
negative for CD1a. B-rapidly accelerated fibrosarcoma (BRAF) 
v600E mutations have been detected in 54% of patients,159 and 
the histiocytic proliferation has been shown to be clonal in some 
studies160,161 but not in others.162 Sustained responses to vemu-
rafenib, a BRAF inhibitor, have been reported in patients with 
BRAF (v600E) mutated Erdheim–Chester disease.163,164
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